Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GALT
- Price
- 2.42
- Stock movement down
- -0.02 (-0.51%)
- Company name
- Galectin Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 248.55M
- Ent value
- 342.95M
- Price/Sales
- 3106.92
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -0.62%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 14.12%
- 1 year return
- 65.11%
- 3 year return
- 21.19%
- 5 year return
- 4.79%
- 10 year return
- 5.01%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GALT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3106.92 |
| Price to Book | - |
| EV to Sales | 4286.84 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 64.06M |
| EPS (TTM) | -0.72 |
| FCF per share (TTM) | -0.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 80.00K |
| Gross profit (TTM) | 53.00K |
| Operating income (TTM) | -39.57M |
| Net income (TTM) | -45.08M |
| EPS (TTM) | -0.72 |
| EPS (1y forward) | -0.44 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 66.25% |
| Operating margin (TTM) | -49457.50% |
| Profit margin (TTM) | -56346.25% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 27.06M |
| Net receivables | 0.00 |
| Total current assets | 28.67M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 28.97M |
| Accounts payable | 2.79M |
| Short/Current long term debt | 104.59M |
| Total current liabilities | 25.26M |
| Total liabilities | 121.45M |
| Shareholder's equity | -92.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -33.68M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -33.68M |
| Dividends paid (TTM) | 210.00K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -155.59% |
| Return on Invested Capital | -372.38% |
| Cash Return on Invested Capital | -278.22% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.88 |
| Daily high | 4.00 |
| Daily low | 3.88 |
| Daily Volume | 134K |
| All-time high | 36.84 |
| 1y analyst estimate | 6.00 |
| Beta | 0.83 |
| EPS (TTM) | -0.72 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Nov 2025 |
Downside potential
Loading...
Downside potential data
| GALT | S&P500 | |
| Current price drop from All-time high | -89.47% | -1.46% |
| Highest price drop | -99.02% | -56.47% |
| Date of highest drop | 17 Nov 2008 | 9 Mar 2009 |
| Avg drop from high | -81.96% | -10.99% |
| Avg time to new high | 339 days | 12 days |
| Max time to new high | 5520 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
248.55M
Marketcap category
Small-cap
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Employees
15
Investor relations
-
SEC filings
CEO
Harold H. Shlevin
Country
USA
City
Norcross
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page